[CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading ->
Despite high public interest in severe air pollution episodes, the real long-term health impacts of air pollution are rarely discussed by news and social media in South and Southeast Asia, says a new study on public perceptions of the problem in one of the most dangerously polluted areas of the world. Image Credits: Vital Strategies. Continue reading ->
Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading ->
NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading ->
The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading ->
Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading ->
Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading ->
A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading ->
The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading ->
SHANGHAI, China - A surge in demand for better healthcare coverage and outcomes and widespread calls for a reduction in high medical treatment costs are driving structural reforms and market-opening initiatives in China's rapidly expanding healthcare market, industry executives, officials and experts have said. The market is forecast to increase from $761 billion in 2017 to nearly $2.4 trillion by 2030. Continue reading ->